 Proto-Oncogene Proteins c-myc
"Proto-Oncogene Proteins c-myc" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Basic helix-loop-helix transcription factors encoded by the c-myc genes. They are normally involved in nucleic acid metabolism and in mediating the cellular response to growth factors. Elevated and deregulated (constitutive) expression of c-myc proteins can cause tumorigenesis.
| Descriptor ID |
D016271
|
| MeSH Number(s) |
D12.776.260.103.813 D12.776.624.664.700.189 D12.776.660.765 D12.776.930.125.813
|
| Concept/Terms |
Proto-Oncogene Proteins c-myc- Proto-Oncogene Proteins c-myc
- Proto Oncogene Proteins c myc
- myc Proto-Oncogene Product p62
- myc Proto Oncogene Product p62
- Proto-Oncogene Proteins myc
- Proteins myc, Proto-Oncogene
- Proto Oncogene Proteins myc
- myc, Proto-Oncogene Proteins
- p62 c-myc
- p62 c myc
- p62(c-myc)
- Proto-Oncogene Products c-myc
- Proto Oncogene Products c myc
- c-myc Proteins
- c myc Proteins
- myc Proto-Oncogene Proteins
- Proto-Oncogene Proteins, myc
- myc Proto Oncogene Proteins
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-myc".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-myc".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-myc" by people in this website by year, and whether "Proto-Oncogene Proteins c-myc" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 1 | 2 | | 1999 | 1 | 0 | 1 | | 2000 | 3 | 0 | 3 | | 2001 | 1 | 0 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 1 | 1 | 2 | | 2004 | 3 | 0 | 3 | | 2005 | 1 | 1 | 2 | | 2007 | 1 | 0 | 1 | | 2008 | 0 | 1 | 1 | | 2009 | 1 | 3 | 4 | | 2010 | 1 | 1 | 2 | | 2011 | 1 | 1 | 2 | | 2012 | 2 | 3 | 5 | | 2013 | 4 | 2 | 6 | | 2014 | 3 | 5 | 8 | | 2015 | 2 | 2 | 4 | | 2016 | 1 | 2 | 3 | | 2017 | 4 | 0 | 4 | | 2018 | 2 | 0 | 2 | | 2019 | 1 | 3 | 4 | | 2020 | 1 | 2 | 3 | | 2021 | 0 | 2 | 2 | | 2022 | 1 | 1 | 2 | | 2023 | 0 | 1 | 1 | | 2024 | 3 | 0 | 3 | | 2025 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-myc" by people in Profiles.
-
Mulkearns-Hubert EE, Hajdari N, Hong ES, Jacobs AP, Gaboriau A, Giltner S, Tannish G, Kay KE, Wang SZ, LaViolette PS, Silver DJ, Hubert CG, Dhawan A, Lathia JD. Connexin 43 drives glioblastoma cancer stem cell phenotypes through a WNK lysine-deficient protein kinase 1-c-MYC signaling axis. Cell Rep. 2025 Sep 23; 44(9):116303.
-
Zhou X, Moreira S, Restelli C, Wang H, Jahangiri S, Aryal S, Tsao E, Zhang P, Niu M, Kumar H, Balde Z, Vujovic A, Liu L, Wong N, Arruda A, Minden MD, Zhou Y, Ravi B, Qi J, Li C, Hope KJ, Lu R. Activation of a nongenetic AHR-ELMSAN1 axis optimizes BET-targeting therapy and suppresses leukemia stem cells in preclinical models. Sci Transl Med. 2025 Aug 06; 17(810):eadn5400.
-
Gomes N, Frederick B, Tentler J, Su TT. Sensitivity to an inhibitor of translation elongation in solid and hematologic cancers. Sci Rep. 2025 Jul 01; 15(1):21328.
-
Kent A, Yee Mon KJ, Hutchins Z, Putzel G, Zhigarev D, Grier A, Jia B, Kortlever RM, Barbet G, Evan GI, Blander JM. A stromal inflammasome Ras safeguard against Myc-driven lymphomagenesis. Nat Immunol. 2025 Jan; 26(1):53-67.
-
Davis LN, Walker ZJ, Reiman LT, Parzych SE, Stevens BM, Jordan CT, Forsberg PA, Sherbenou DW. MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance. Clin Cancer Res. 2024 Jul 15; 30(14):3023-3035.
-
Rodriguez-Blanco J, Salvador AD, Suter RK, Swiderska-Syn M, Palomo-Caturla I, Kliebe V, Shahani P, Peterson K, Turos-Cabal M, Vieira ME, Wynn DT, Howell AJ, Yang F, Ban Y, McCrea HJ, Zindy F, Danis E, Vibhakar R, Jermakowicz A, Martin V, Coss CC, Harris BT, de Cubas A, Chen XS, Barnoud T, Roussel MF, Ayad NG, Robbins DJ. Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models. J Clin Invest. 2024 Jun 17; 134(15).
-
Alderman C, Anderson R, Zhang L, Hughes CJ, Li X, Ebmeier C, Wagley ME, Ahn NG, Ford HL, Zhao R. Biochemical characterization of the Eya and PP2A-B55a interaction. J Biol Chem. 2024 07; 300(7):107408.
-
Zayac AS, Landsburg DJ, Hughes ME, Bock AM, Nowakowski GS, Ayers EC, Girton M, Hu M, Beckman AK, Li S, Medeiros LJ, Chang JE, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi YH, Epperla N, Bond DA, Farooq U, Saad M, Evens AM, Pandya K, Naik SG, Kamdar M, Haverkos B, Karmali R, Oh TS, Vose JM, Nutsch H, Rubinstein PG, Chaudhry A, Olszewski AJ. High-grade B-cell lymphoma, not otherwise specified: a?multi-institutional retrospective study. Blood Adv. 2023 11 14; 7(21):6381-6394.
-
Rankin AW, Siegele B, Gross TG. Discordance between detection of MYC rearrangement by immunohistochemistry versus fluorescent in situ hybridization in Burkitt lymphoma. Pediatr Blood Cancer. 2022 12; 69(12):e29804.
-
Amaya ML, Inguva A, Pei S, Jones C, Krug A, Ye H, Minhajuddin M, Winters A, Furtek SL, Gamboni F, Stevens B, D'Alessandro A, Pollyea DA, Reigan P, Jordan CT. The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation. Blood. 2022 01 27; 139(4):584-596.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|